BioSpace News Archive

Shuttle Pharmaceuticals Holdings, Inc. today announced that its Chief Executive Officer, Dr. Anatoly Dritschilo, will be participating in the Emerging Growth Conference on March 6, 2024.

Viridian Therapeutics, Inc. today announced that senior management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Monday, March 11 at 2:00 p.m. ET.

Mirum Pharmaceuticals, Inc. today announced that it will participate in the following upcoming investor conferences.

Twist Bioscience Corporation today announced European Union (EU) in vitro diagnostic regulations (IVDR) compliant Twist Precision Dx next-generation sequencing (NGS) Products.

Hologic, Inc. and its subsidiary, Biotheranostics, Inc., announced newly published study results revealing that use of the Breast Cancer Index® test led to physicians changing their long-term anti-estrogen treatment recommendations for 40% of patients with early-stage hormone receptor-positive breast cancer.

Allogene Therapeutics, Inc. today announced that it will report fourth quarter and full year 2023 financial results and provide a business update on March 14, 2024, after the close of the market.

Simulations Plus, Inc. today announced that, through a joint proposal with the University of Bath’s Department of Life Sciences and other university partners, it has been awarded a new funded grant from the U.S. Food and Drug Administration (FDA).

Applied Energetics, Inc. today announced that Dr. James Harrison has been named director of new product innovation for the company, effective April 3, 2024.

MAIA Biotechnology, Inc. today published a 2024 Letter to Shareholders by Chairman and Chief Executive Officer Vlad Vitoc, M.D., detailing the Company’s immuno-oncology cancer treatment candidates and development pipeline.

ModeX Therapeutics Inc., an OPKO Health company, announced results from a Phase 1 clinical study of SAR441236, its trispecific broadly neutralizing antibody against the human immunodeficiency virus, at the 2024 Conference on Retroviruses and Opportunistic Infections in Denver, Colorado.